Allergic Aces Soar: $DBVT, $XNCR, $VRNA, $ALLK Show Remarkable +13.72% Weekly Performance Surge
Robots for this group tickers :
Swing Trader, Long Only: Growth Model (FA) - 30-day Annualized Return +20%
Trend Trader, Long Only with Inverse: Advanced Growth Model (FA) - 30-day Annualized Return +12%
In the dynamic world of finance, where trends shift like the wind, a distinctive group of stocks has recently caught the attention of investors — the Allergic companies. Comprising DBVT, XNCR, VRNA, and ALLK, this group has exhibited a remarkable +13.72% surge in performance over the past week, making it a subject of interest and speculation in financial circles.
Positive Outlook and Technical Indicators
The positive outlook for these stocks is substantiated by the MA50MA10 Indicator, which indicates a favorable trajectory. Tickeron, a reliable financial analysis tool, reinforces this positivity, predicting a further increase of over 4.00% within the next month with a 40% likelihood. The daily ratio of advancing to declining volumes over the last month was an encouraging 1.68 to 1.
Two stocks within this thematic group showcase a positive trend based on the MA50 indicator with an average likelihood of 84%, highlighting a potential sustained upward movement.
Market Capitalization Overview
The average market capitalization across the group stands at 640.8M, with individual valuations ranging from 157.5M to 1.1B. XNCR leads the pack with a valuation of 1.1B, while ALLK is the lowest valued at 157.5M.
High and Low Price Notables
Weekly price growth across all stocks in the group averaged an impressive 13.09%, demonstrating the theme's robust performance. ALLK took the lead with a substantial 34.46% increase, while VRNA experienced a modest decline of 0.96%. Notably, Verona Pharma (VRNA) faced a setback, declining by -12.24% in the week ending 5/17/23, while DBV Technologies SA (DBVT) soared as a top weekly gainer, rising by +18.59% on 5/12/23.
Volume Dynamics
Despite a weekly average volume decline of -38.78%, the group exhibited positive signs with a monthly average volume growth of 16.98% and a quarterly growth of 126.06%. A standout moment was observed in DBV Technologies SA's stock, with consecutive daily gains reaching record-breaking levels, indicating substantial market interest.
Individual Stock Analysis
-
DBVT - Seizing an Upward Trend: DBVT broke its lower Bollinger Band on November 14, 2023, suggesting a potential upward movement. Historical data indicates that in 39 of 46 instances where DBVT's price broke its lower Bollinger Band, it rose further in the following month, with odds favoring an 85% likelihood. The current price of $0.81, having crossed the support line at $0.75, suggests a potential rebound. Recent trends show a -21% downtrend for the month of 11/06/23 - 12/07/23, but a positive +7% uptrend in the week of 11/30/23 - 12/07/23.
-
XNCR - Riding the Upward Trend: XNCR's 10-day moving average crossed above the 50-day moving average on November 28, 2023, signaling a bullish trend. Historical data indicates that in 10 of 12 instances where this crossover occurred, the stock continued to move higher over the following month, with odds favoring an 83% likelihood. The current price of $20.25, below the lowest support line at $23.28, presents a potential buying opportunity. Recent trends show a +10% uptrend throughout the month of 11/06/23 - 12/07/23 and a further +10% uptrend during the week of 11/30/23 - 12/07/23.
-
VRNA - Stochastic Oscillator Signals Potential Upside: VRNA's Stochastic Oscillator moved out of oversold territory on December 04, 2023, indicating a potential bullish signal. Historical data shows that in 56 of 68 instances where the Stochastic Indicator left the oversold zone, the stock moved higher in the following days, with odds favoring over 82%. The current price of $14.62, having crossed the resistance line at $13.00, suggests potential upward movement. Recent trends show a -10% downtrend throughout the month of 11/06/23 - 12/07/23, but a positive +0.96% uptrend in the week of 11/30/23 - 12/07/23.
In summary, the Allergic companies theme presents a compelling case for investors seeking opportunities in a trending sector. With positive indicators and individual stocks exhibiting favorable patterns, this thematic group offers a nuanced landscape for potential gains. Investors are advised to conduct further due diligence and consider their risk tolerance before making investment decisions in this dynamic market.
DBVT sees MACD Histogram crosses below signal line
DBVT saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on January 28, 2025. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 42 instances where the indicator turned negative. In of the 42 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 43 cases where DBVT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Momentum Indicator moved below the 0 level on February 19, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on DBVT as a result. In of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DBVT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Bullish Trend Analysis
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where DBVT advanced for three days, in of 196 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 83 cases where DBVT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. DBVT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.669) is normal, around the industry mean (12.496). P/E Ratio (0.000) is within average values for comparable stocks, (84.451). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.603). DBVT has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (75.432) is also within normal values, averaging (251.218).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DBVT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
General Information
a developer of therapeutics to treat autoimmune and allergic diseases, cancer and other conditions
Industry Biotechnology